Hankang Portfolio | Hankang Capital's Early Conviction in Oral Macrocyclic Peptides Validated by PepStar's $1.275 Billion Transaction with Gilead

Hankang Capital is a specialist investor dedicated to the innovative biotechnology sector. Driven by deep industry insight and a rigorous investment methodology, we identify and support top-tier teams developing inflection-point candidates across diverse modalities to deliver significant clinical value...
By consistently nurturing early-stage breakthroughs into world-class therapies, we serve as a devoted cultivator empowering biomedical innovation for the benefit of patients worldwide.
Our portfolio is globally recognized for its scientific and technological excellence, having forged extensive out-licensing collaborations and co-development partnerships with leading multinational corporations (MNCs). Our team and advisory network bring extensive hands-on expertise in drug discovery, clinical development, regulatory affairs (NMPA & FDA), business development and commercialization.